Paper Details

  1. Home
  2. Paper Details

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

Author: CampieriM, CastiglioneF, CottoneM, LochsH, PranteraC, ScribanoM L, SturnioloG C

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Rifaximin 800 mg b.d. was superior to placebo in inducing clinical remission of active Crohn's disease. The number of the failures in the placebo group was significantly higher than those who received rifaximin 800 mg b.d.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Clinicians often employ antibiotics in Crohn's disease. Rifaximin is active against bacteria frequently found in the intestinal mucosa of Crohn's disease patients. AIM: To evaluate the difference in efficacy between once and twice/daily oral administration of rifaximin and placebo in th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1365-2036.2006.02879.x

データ提供：米国国立医学図書館（NLM）

Treating Crohn's Disease with Rifaximin

[Crohn's disease] is a chronic inflammatory bowel disease that can significantly impact quality of life. This study investigated the [efficacy of rifaximin], an [antibiotic], in treating [active Crohn's disease]. The researchers conducted a [multicentre, double blind, randomized, placebo-controlled trial] involving [83 patients] and compared the effectiveness of [different dosing regimens] of rifaximin.

Rifaximin: A Potential Treatment Option for Crohn's Disease

The study found that [rifaximin 800 mg b.d.] was [superior to placebo] in inducing [clinical remission] in patients with [active Crohn's disease]. The researchers also noted that rifaximin appeared to be more effective in patients with [elevated C-reactive protein values].

Finding Relief from Crohn's Disease

Imagine a camel seeking a cool oasis in the scorching desert. This research highlights the potential of [rifaximin] to provide relief for those living with [Crohn's disease]. The study underscores the importance of [individualized treatment approaches] and the need for [ongoing research] to explore the full potential of this antibiotic.

Dr. Camel's Conclusion

This research offers hope for patients with Crohn's disease by providing evidence for the efficacy of rifaximin in inducing clinical remission. It emphasizes the importance of personalized treatment plans and the need for continued research to optimize the use of rifaximin in managing this complex condition.

Date :
  1. Date Completed 2006-06-29
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

16611272

DOI: Digital Object Identifier

10.1111/j.1365-2036.2006.02879.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.